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Abstract
Ischemic stroke is the second leading cause of death worldwide. Only one moderately effective therapy exists, albeit with
contraindications that exclude 90% of the patients. This medical need contrasts with a high failure rate of more than 1,000
pre-clinical drug candidates for stroke therapies. Thus, there is a need for translatable mechanisms of neuroprotection and
more rigid thresholds of relevance in pre-clinical stroke models. One such candidate mechanism is oxidative stress.
However, antioxidant approaches have failed in clinical trials, and the significant sources of oxidative stress in stroke are
unknown. We here identify NADPH oxidase type 4 (NOX4) as a major source of oxidative stress and an effective therapeutic
target in acute stroke. Upon ischemia, NOX4 was induced in human and mouse brain. Mice deficient in NOX4 (Nox42/2) of
either sex, but not those deficient for NOX1 or NOX2, were largely protected from oxidative stress, blood-brain-barrier
leakage, and neuronal apoptosis, after both transient and permanent cerebral ischemia. This effect was independent of age,
as elderly mice were equally protected. Restoration of oxidative stress reversed the stroke-protective phenotype in Nox42/2
mice. Application of the only validated low-molecular-weight pharmacological NADPH oxidase inhibitor, VAS2870, several
hours after ischemia was as protective as deleting NOX4. The extent of neuroprotection was exceptional, resulting in
significantly improved long-term neurological functions and reduced mortality. NOX4 therefore represents a major source
of oxidative stress and novel class of drug target for stroke therapy.
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Introduction
Ischemic stroke has outstanding medical relevance as it is the
second leading cause of death in industrialized countries [1]. Due
to the aging of the population, the incidence of stroke is projected
to rise even further in the future [2]. Despite tremendous research
activity, with more than 100 clinical trials in human stroke patients
[3], only one therapy approved by the United States Food and
Drug Administration is available, i.e., thrombolysis using recom-
binant tissue plasminogen activator (rt-PA). However, the efficacy
of rt-PA on functional outcomes is moderate at best, and more
than 90% of all stroke patients must be excluded from rt-PA
treatment because of over 25 labeled contraindications. Therefore,
there is an unmet need for more effective therapies in acute stroke.
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Although a plethora of drugs for the treatment of acute stroke
are effective in animal models, their translation into clinical
practice has completely failed [3,4]. As a result, many pharma-
ceutical companies have withdrawn from drug discovery in this
area. To overcome this lack of clinically effective neuroprotective
drugs, innovative strategies are urgently needed to identify
pathways that can be targeted with innovative therapies [5].
Higher quality study designs are also required [6,7].
One such high-potential pathway in ischemic stroke may be the
occurrence of oxidative stress, i.e., the increased occurrence of
reactive oxygen species (ROS) above physiological levels. Oxida-
tive stress has been suggested for many years to cause tissue
damage and neuronal death. The toxicity of ROS can be further
increased by nitric oxide to produce reactive nitrogen species such
as peroxynitrite (ONOO2), a molecule that causes oxidation and
nitration of tyrosine residues on proteins [8]. Disappointingly,
there is no conclusive evidence of a causal link between oxidative
stress and the development of disease, and there is no successful
therapeutic application targeting oxidative stress. To date, clinical
attempts to scavenge ROS by applying antioxidants did not result
in clinical benefit [9] or even caused harm [10,11]. However, the
characterization of the relevant enzymatic sources of oxidative
stress may allow therapeutic targeting of oxidative stress by
preventing the formation of ROS in the first place, instead of
scavenging ROS after they have been formed.
A potential source of ROS are NADPH oxidases, the only
known enzyme family that is only dedicated to ROS production
[12]. Four rodent genes of the catalytic subunit NOX, Nox1, Nox2,
Nox3, and Nox4, have been identified, of which Nox1, Nox2, and
Nox4 are expressed in the vasculature. NOX4 is the most
abundant vascular isoform; its expression is even higher in
cerebral than in peripheral blood vessels [13] and, further,
induced in stroke [14]. Therefore, we hypothesized that NOX4 is
the most relevant source of ROS in stroke.
To test this hypothesis, we generated constitutively NOX4-
deficient (Nox42/2) mice and directly compared them to NOX1-
deficient (Nox1y/2) and NOX2-deficient (Nox2y/2) mice. NOX4
has been implicated in the regulation of systemic and hypoxic
vascular responses. Therefore, we had to exclude systemic vascular
effects of NOX4 deletion on blood pressure, which may affect
stroke outcome independent of a specific neuronal or neurovas-
cular mechanism. Finally, to examine the therapeutic potential of
NOX4 as a drug target, we infused the specific NADPH oxidase
inhibitor VAS2870 [15] after ischemia, thus mirroring the clinical
scenario.
Results
NOX4 Is Induced during Ischemic Stroke in Mice and
Humans
Because NOX4 mRNA is expressed at higher levels in cerebral
than in peripheral blood vessels [13] and is induced in stroke [14],
we first sought to validate these data not only at the mRNA but
also at the protein level. In all experiments, we followed current
guidelines defining methodological standards for experimental
stroke studies [4,6,7,16,17]. Here we chose a model of acute
ischemic stroke in which mice are subjected to transient middle
cerebral artery occlusion (tMCAO). This disease model is thought
to involve oxidative stress and an induction of Nox4 expression
[18]. Indeed, expression of NOX4 mRNA was significantly higher
12 h and 24 h after tMCAO in the basal ganglia and neocortex of
wild-type mice than in sham-operated controls, in which basal
NOX4 expression was low (Figure 1A). This result was validated
by immunohistochemistry using a specific NOX4 antibody. We
detected a stronger staining in neurons and cerebral blood vessels
in wild-type mice subjected to tMCAO than in sham-operated
controls. Although immunohistochemistry is not quantitative, this
finding suggests higher levels of NOX4 protein (Figure 1B).
Importantly, NOX4 staining was also stronger in brain samples
from stroke patients. Although NOX4 was barely detectable in
healthy brain regions, clear positive labeling of NOX4 was seen in
neurons and vascular endothelial cells from the forebrain cortex of
stroke patients. This finding was confirmed by double labeling for
NeuN (a neuronal marker) or von Willebrand factor (an
endothelial marker) and NOX4 in brain tissue (Figure 1B). These
data indicate that NOX4 protein is induced during brain ischemia
in mice, and this observation would be in agreement with a major
functional role for NOX4 in ischemic stroke. Our limited
observations in a small number of human cases provide some
support to the hypothesis that these processes are also important in
human stroke.
Nox42/2 but Neither Nox1y/2 nor Nox2y/2 Mice Are
Protected in Both Transient and Permanent Ischemic
Stroke
We first subjected 6- to 8-wk-old male Nox42/2 mice to tMCAO
and, after 24 h, assessed infarct volumes by staining brain sections
with 2,3,5-triphenyltetrazolium chloride (TTC) (Figure 2A). Infarct
volumes were significantly smaller, by approximately 75%, in male
Nox42/2 mice than in sex-matched wild-type controls
(25.5614.8 mm3 versus 78.7619.5 mm3, respectively). The smaller
infarct volume was functionally relevant: compared with wild-type
mice, Nox42/2 mice had significantly better overall neurological
function (Bederson score 1.260.7 in Nox42/2 mice versus 3.761.1
in wild-type mice) as well as better basal motor function and
coordination (grip test score 4.360.7 in Nox42/2 mice versus
1.761.3 in wild-type mice) 24 h after tMCAO (Figure 2B). Gender
can significantly influence stroke outcome in rodents [4,16,17].
Therefore, we also subjected female Nox42/2 mice to 60 min of
tMCAO. In line with the results in male mice, Nox4-deficient
female mice also developed significantly smaller infarctions
Author Summary
Stroke is the second leading cause of death worldwide.
Today, only one approved therapy exists—a drug that
breaks down blood clots—the effectiveness of which is
moderate, and it can only be used in about 10% of
patients because of contraindications. New therapeutic
strategies that are translatable to humans and more rigid
thresholds of relevance in pre-clinical stroke models are
needed. One candidate mechanism is oxidative stress,
which is the damage caused by reactive oxygen species
(ROS). Antioxidant approaches that specifically target ROS
have thus far failed in clinical trials. For a more effective
approach, we focus here on targeting ROS at its source by
investigating an enzyme involved in generating ROS,
known as NADPH oxidase type 4, or NOX4. We found that
NOX4 causes oxidative stress and death of nerve cells after
a stroke. Deletion of the NOX4-coding gene in mice, as
well as inhibiting the ROS-generating activity of NOX with
a pharmacological inhibitor, reduces brain damage and
improves neurological function, even when given hours
after a stroke. Importantly, neuroprotection was preserved
in old male and female Nox42/2mice as well as in Nox42/2
mice subjected to permanent ischemia. NOX4 thus
represents a most promising new therapeutic target for
reducing oxidative stress in general, and in brain injury due
to stroke in particular.
Role of NOX4 in Stroke
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(30.166.7 mm3 versus 89.5622.2 mm3, respectively) and less
severe neurological deficits (p,0.001) than female controls
(Figure 2A and 2B). Histological analysis revealed that all infarcts
in Nox42/2 mice were restricted to the basal ganglia (arrow in
Figure 2A and 2C), whereas in wild-type mice, the neocortex was
also consistently affected. Serial magnetic resonance imaging of
living mice up to 6 d after stroke showed that in Nox42/2 mice the
infarct volume did not increase over time, thus indicating that
deletion of the Nox4 gene provides sustained protection against
stroke (Figure 2C). Moreover, infarcts always appeared hyperin-
tense on blood-sensitive constructive interference in steady state
(CISS) sequences. Hypointense areas, which typically indicate
intracerebral hemorrhage, were absent from Nox42/2 mice and
wild-type controls. This finding excludes the possibility of an
increased rate of bleeding complications caused by Nox4 deficiency.
To establish any potential specificity of this function for NOX4
compared to NOX1 and NOX2 in stroke, we carried out identical
experiments in 6- to 8-wk-old Nox1y/2 and Nox2y/2 mice.
However, in contrast to Nox42/2 mice, we observed no protection
in these animals, neither in terms of infarct volumes nor on
functional outcomes on day 1 after tMCAO, even with large
subject sample sizes (n=19 for Nox2y/2 mice, p.0.05; Figure 2A).
Ischemic stroke is usually a disease of the elderly and,
consequently, one should verify any stroke-protective effects
observed in young adult laboratory animals also in an older
cohort [4,16,17]. Indeed, 18- to 20-wk-old Nox42/2 mice also
developed significantly smaller brain infarctions (27.8615.1 mm3
versus 81.8619.0 mm3, respectively) and less severe neurological
deficits than age-matched controls, thereby confirming our results
in young animals (Figure 2B). We also determined the functional
outcome and mortality of 6- to 8-wk-old male Nox42/2 mice and
matched wild-type controls over a longer time period after
ischemic stroke (Figure 2D). Five days after 60 min of tMCAO, 15
of 15 wild-type mice (100%) had died, which is in line with
previous reports [19]. In contrast, seven of ten Nox42/2 mice
(70%) survived until day 5, and five of these were still alive after
1 wk (p=0.0039) (Figure 2D). In line with these findings, Nox4-
deficient mice showed significantly better Bederson scores than
controls over the whole observation period, and neurological
deficits remained low until day 7 (Figures 2D and S4).
According to the current experimental stroke guidelines
[4,16,17], any protective effect also requires evaluation in models
of both transient and permanent ischemia. We therefore subjected
Nox42/2 mice to filament-induced permanent middle cerebral
artery occlusion (pMCAO), a procedure in which no tissue
reperfusion occurs (Figure 2E). In the absence of Nox4, infarct
volumes (66.7628.6 mm3 versus 120.1615.6 mm3, p,0.05) and
neurological deficits (Bederson score 2.361.7 versus 3.460.8,
p,0.05) at day 1 after pMCAO were significantly reduced
compared with those in wild-type controls, although to a lesser
extent than they were in the tMCAO model (Figures 2E and S5).
Brain infarctions following filament-induced pMCAO are large,
and the infarct borders are often not very well defined, which
limits the accuracy of any estimation on infarct volumes. We
therefore used another model of permanent stroke, cortical
photothrombosis, to further verify our findings. Here, the lesions
are restricted to the cortex and highly reproducible in size and
location. Moreover, photothrombosis has been shown to induce
early and profound ROS formation and blood-brain-barrier
leakage [20,21], two key readout parameters of the present
investigation. Importantly, photothrombosis-induced infarct vol-
umes were as reduced in Nox42/2 mice relative to wild-type mice
(3.364.6 mm3 versus 25.0612.8 mm3, respectively, a difference
of 86.8%; Figure 2F) as they were in the tMCAO model.
No Apparent Vascular Phenotype of Nox42/2 Mice Other
Than in Stroke
Based on the physiological distribution of NOX4 in kidney [22],
lung [23], and aorta [24], as well as cell biology data obtained
using small interfering RNA approaches [23], one would predict
basal phenotypes in a Nox42/2 mouse, such as arterial
hypotension, reduced hypoxic pulmonary hypertension, and
altered renal function. Importantly, these effects could potentially
modulate or interfere with stroke outcome even in the absence of a
specific neuronal or neurovascular mechanism. Surprisingly,
systemic elimination of Nox4 did not result in any apparent
abnormal vascular phenotype (Text S1; Figures S1 and S2; Table
S1). In particular, blood pressure was normal, and hypoxic
pulmonary hypertension still occurred despite a 20-fold induction
of NOX4 in wild-type animals [23]. In contrast, Nox1- and
p47phox-deficient mice (a Nox2 subunit) have a lower basal blood
pressure, and their blood-pressure response to angiotensin II is
reduced [25–27]. Our data suggest that any phenotype caused by
deleting Nox4, unlike those caused by deleting Nox1 and Nox2,
would indeed be brain-specific.
Protection from Ischemic Stroke in Nox42/2 Mice Is a
Result of Reduced Oxidative Stress, Neuronal Apoptosis,
and Blood-Brain-Barrier Leakage
Next we sought to elucidate the underlying mechanisms of this
NOX4-specific neurotoxicity in stroke. NOX4 can form superox-
ide or H2O2, which can interact with nitric oxide to form reactive
nitrogen species. Therefore, we stained brain sections with broad-
spectrum indicators of oxidative/nitrative stress, i.e., dihydroethi-
dium [28] and nitrotyrosine [8]. At 12 h and 24 h after tMCAO,
brains from wild-type mice exhibited a significantly larger amount
(by a factor of 2.5–3.5) of ROS in neurons than brains from sham-
operated animals, as quantified by dihydroethidium staining
(Figure 3A). Neurons from Nox42/2 mice, in contrast, showed
only very small ischemia-induced increases in ROS relative to
those in sham-operated controls (p.0.05). ROS formation from
neurons after 24 h was also significantly reduced in Nox42/2 mice
subjected to pMCAO (Figure S6). Because the dihydroethidium
stain may also indicate oxidative chemistry events, including
formation of ONOO2 and nitration of protein tyrosine residues
[8], we analyzed the extent of protein nitration in Nox42/2 and
wild-type mice subjected to tMCAO. In agreement with our
findings on the generation of ROS, tissue nitration occurred to a
lesser extent in ischemic brains from Nox42/2 mice than in those
from wild-type controls (Figure 3B). Oxidative chemistry events
such as the formation of ROS and peroxynitrite, as detected by
Figure 1. Induction of NOX4 expression after ischemic stroke in mice and humans. (A) Relative gene expression of Nox4 in the ischemic
basal ganglia (left) and cortex (right) of wild-type mice after sham operation and 4 h, 12 h, and 24 h after tMCAO (n= 5). *, p,0.05, one-way ANOVA,
Bonferroni post-hoc test, compared with sham-treated controls. (B) Immunohistochemical detection of NOX4 protein in ischemic brains of wild-type
mice (after sham operation or tMCAO, day 1) and humans (samples from stoke patients, after routine autopsy). We compared NOX4 immunolabeling
in the ischemic forebrain cortex and the unaffected contralateral side. In ischemic samples, NOX4 was predominantly expressed in neurons
(arrowheads) and endothelial cells (arrows). This distribution was confirmed by visualization of NOX4 and NeuN or NOX4 and von Willebrand Factor in
the same structures. All scale bars represent 100 mm.
doi:10.1371/journal.pbio.1000479.g001
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dihydroethidium staining and nitrotyrosine immunolabeling, can
induce neuronal apoptosis, which is a well-established mechanism
of tissue damage in ischemic stroke [29,30]. Indeed, superimposed
TUNEL and NeuN immunolabeling revealed widespread apop-
tosis of neurons in wild-type mice 24 h after stroke onset
(Figure 3C). In contrast, the number of apoptotic neurons in
Nox42/2 mice subjected to tMCAO was significantly lower, and
the basal apoptotic turnover rate in Nox42/2 mice fell within the
range found in sham-operated mice (p.0.05) (Figure 3C).
We also detected NOX4 in cerebral blood vessels (Figure 1B,
white arrow indicates endothelial cells). Therefore, we hypothe-
sized that Nox4 deficiency also influences the disruption of the
blood–brain barrier and edema formation mediated by ROS [31].
Integrity of the blood–brain barrier was preserved in Nox42/2
mice on day 1 after tMCAO. This finding correlated with
significantly less brain edema in Nox42/2 mice than in wild-type
controls, as assessed by the extent of extravasation of Evans blue
stain (8.065.9 mm3 in Nox42/2 mice versus 96.265.9 mm3 in
wild-type mice). Importantly, almost no brain edema was seen in
the brain regions where infarcts were regularly present in Nox42/2
mice (basal ganglia; Figure 3D, area delineated by the broken
white line). This result indicates that the lesser edema seen in the
Nox42/2 mice was a specific phenomenon and mechanistically
relevant but was not due to smaller infarct volumes.
Treatment with the NOX Inhibitor VAS2870 Effectively
Protects Ischemic Brain Damage Even When Applied
After Stroke
Finally, we wanted to examine whether these genetic insights
into the biology of oxidative stress in stroke and the role of NOX4
in general can be translated into a therapeutic intervention.
Importantly, this intervention would have to be effective post-
stroke and ideally it would be pharmacological. Therefore, we
examined the efficacy of a validated, low-molecular-weight
NADPH oxidase inhibitor, VAS2870 [15,32–34], in vital brain
slices and in vivo. VAS2870 equally inhibits the ROS-generating
activity of all NOX subunits, i.e., NOX1, NOX2, and NOX4.
Vital brain slices [35] taken from wild-type mice 12 h after
tMCAO produced significantly less ROS after pretreatment with
10 mMVAS2870, as did brain slices from untreated Nox42/2 mice
(Figure 4A). Importantly, incubating ischemic slices from Nox42/2
mice with VAS2870 had no additional inhibitory effect on
superoxide formation (Figure 4A). This finding further underlines
the extraordinary role of NOX4 in generating oxidative stress
during the course of ischemic stroke, while other NOX isoforms
such as NOX1 or NOX2 are obviously less relevant.
To determine whether VAS2870 is also active when applied in
vivo, we administered 2 mg of VAS2870 intrathecally to wild-type
mice 2 h and 12 h after tMCAO. This experimental therapeutic
approach significantly reduced brain infarct volumes (20.764.0 mm3
in VAS2870-treated mice versus 82.466.4 mm3 in vehicle-treated
controls) and significantly improved neurological function, to the
same extent as observed for the deletion of Nox4 in mice (Figure 4B
and 4C). Moreover, less oxidative stress was detected in ischemic
brains from VAS2870-treated animals than in those from vehicle-
treated controls (Figure 4D). Again, post-stroke application of
VAS2870 to Nox42/2 mice had no additive neuroprotective or
superoxide-lowering effect compared to the outcomes in wild-type
animals treated with VAS2870 or untreated Nox42/2 mice
(Figure 4B–4D). This observation is consistent with our ex vivo
findings in ischemic brain slices and reaffirms that NOX4 rather than
NOX1 or NOX2 is critically involved in the pathophysiology of
ischemic stroke. Another, less specific inhibitor that also targets
molecules other than NADPH oxidases [36,37], apocynin, had no
effect on infarct size or functional outcome when given post-stroke
and did not reduce the formation of ROS in vivo (Figure 4B and 4C).
To further examine whether the neuroprotective effect observed
in Nox42/2 mice is specifically related to reduced ROS formation
and not due to other nonspecific or developmental defects, we
performed a rescue experiment by restoring cerebral ROS levels in
Nox42/2 mice during the course of ischemic stroke by applying
exogenous H2O2 (Figure 4B–4D). Indeed, intrathecal administra-
tion of H2O2 rescued the phenotype in Nox4
2/2 mice, and infarct
volumes, functional deficits, and stroke-induced ROS formation
returned to the levels observed in wild-type mice (Figure 4B–4D).
Discussion
Here we identify NOX4 as a relevant molecular source of
oxidative stress in cerebral ischemia, including some cases of
human stroke. Our data suggest that NOX4-mediated oxidative
stress leads to neuronal damage via leakage of the blood–brain
barrier and neuronal apoptosis—two pathophysiological hallmarks
of ischemic stroke. The extent of neuroprotection conferred by the
absence of NOX4 in male and female Nox42/2 mice was
exceptional and preserved in old animals. Importantly, the
outcomes of these genetic experiments were mimicked when we
pharmacologically inhibited NADPH oxidases within a clinically
relevant time after induction of stroke. We consider this a key
Figure 2. Nox4 deficiency confers long-term neuroprotection and reduces mortality after acute ischemic stroke in young adult and
aged mice of either sex. (A) Upper panel shows representative TTC staining of three corresponding coronal brain sections of 6- to 8-wk-old male
and female wild-type (WT) mice, male Nox1y/2 mice, male Nox2y/2 mice, and male and female Nox42/2 mice, as well as 18- to 20-wk-old male wild-
type and Nox42/2mice on day 1 after tMCAO. The ischemic infarcts (white) appear smallest in the Nox42/2mice of either age or sex (arrows), and this
result was confirmed by infarct volumetry (lower panel). ***, p,0.0001, and **, p,0.001, one-way ANOVA, Bonferroni post-hoc test compared with
wild-type mice (n= 8–19 per group). (B) Neurological Bederson score (upper panel) and motor score (lower panel) on day 1 after tMCAO in the eight
mouse groups indicated above. (C) Serial magnetic resonance images of cerebral infarcts 1 d and 6 d after tMCAO in wild-type and Nox42/2 mice
(lower panel). The broken white lines show hyperintense ischemic lesions on day 1 after tMCAO in wild-type and Nox42/2 mice. Infarcts on day 1 are
smaller in Nox42/2 mice than in wild-type mice and remain restricted to the basal ganglia on day 6. Hematoxylin and eosin staining confirmed
neuronal damage in the cortex of wild-type mice 24 h after tMCAO (top panel, left), whereas cortical integrity was preserved in Nox42/2 mice (top
panel, right). (D) Mortality (upper panel) and long-term functional outcome (Bederson score, lower panel) in 6- to 8-wk-old male Nox42/2 mice and
wild-type controls. Survival curve (upper panel): **, p=0.0039, log-rank test compared with wild-type mice (n= 10–15 per group). Long-term
outcome (lower panel): ***, p,0.0001, and *, p,0.05, one-way ANOVA, Bonferroni post-hoc test compared with wild-type mice (n=10–15 per group).
(E) Upper panel shows representative TTC staining of three corresponding coronal brain sections of 6- to 8-wk-old male wild-type mice (left) and
matching Nox42/2 mice (right) on day 1 after pMCAO. Lower panel: Infarct volumes as measured by infarct volumetry (left) and Neurological
Bederson score (right). Nox4 deficiency also protects the brain from permanent ischemia. **, p,0.001, and *, p,0.05, two-tailed Student’s t-test
compared with wild-type mice (n= 7–11 per group). (F) Representative coronal brain sections of wild-type and Nox42/2mice stained with TTC on day
1 after permanent cortical photothrombosis (PT) (upper panel). Cortical infarctions are smaller in the absence of NOX4 (arrow). The lower panel shows
infarct volumes in wild-type and Nox42/2 mice on day 1 after cortical photothrombosis. **, p,0.001, two-tailed Student’s t-test compared with wild-
type mice (n= 7 per group). All scale bars represent 100 mm.
doi:10.1371/journal.pbio.1000479.g002
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finding for the wider concept of oxidative stress, which might also
be of relevance for other disease states, such as neurotrauma and
neuroinflammation, where oxidative stress, blood–brain barrier
damage, and neurotoxicity are involved. Rather than focusing on
antioxidants and the disappointing outcomes of their application,
the identification of the relevant source of oxidative stress and
preventing its formation may represent an approach with clinical
potential.
The hypothesis that free radicals are involved in acute ischemic
stroke and account for secondary infarct growth dates back to the
1970s [38] but has remained unproven [38,39]. The extent of
neuroprotection that we observed is exceptional compared with
that seen in many other pre-clinical stroke studies, in which the
reduction of infarct size usually does not exceed 30%–40% [40].
Such moderate reductions of infarct volume have not translated
into improvement of neurological status [3]. Most notably,
continuous assessment of functional deficits until 7 d after stroke
revealed that Nox4-null mice indeed showed a better amplitude
rather than simply altered kinetics of recovery. This protection in
Nox42/2 mice was further underlined by a significantly reduced
post-stroke long-term mortality.
Secondary infarct growth mediated for example by edema
formation or hemorrhagic transformation is common during the
course of brain ischemia and can lead to worsening of neurological
symptoms [39]. Serial magnetic resonance imaging revealed that
infarcts in Nox42/2 mice remain small, even at later stages of
infarct development, and signs of intracerebral hemorrhage were
consistently absent, thus indicating that NOX4 inhibition is likely
to be safe and persistently effective.
A plethora of compounds have provided neuroprotection in
animal models of brain ischemia, but they all failed in human
clinical trials [4]. This translational roadblock has been attributed
mainly to inadequate pre-clinical study design and severe
methodological shortcomings. Important confounding factors are
a lack of randomization or rater-blinded evaluation of study
results, and use of only one stroke model [16]. Strictly adhering to
current expert recommendations for basic stroke trials, we here
demonstrate that in the absence of NOX4, brain tissue can be
salvaged after ischemia or reperfusion injury (as occurs in the
tMCAO model). Most importantly, neuroprotection was preserved
in old male and female Nox42/2 mice as well as in Nox42/2 mice
subjected to permanent ischemia (i.e., cortical photothrombosis or
pMCAO). Compared to in the tMCAO model, however, the
reduction of infarct size in the pMCAO model was less
pronounced though still significant. Distinct pathomechanisms
that can be positively influenced only in the presence of tissue
reperfusion, i.e., after tMCAO but not pMCAO, such as
progressive thrombus formation in the cerebral microvasculature
[41], might account for this quantitative difference. Indeed,
preliminary results suggest that clotting is attenuated in the
cerebral vessels of Nox42/2 mice subjected to tMCAO but not
pMCAO (unpublished data). Clearly, elimination of NOX4
remains beneficial in the absence of arterial recanalization, a
condition frequently observed in human stroke.
In our experiments, deficiency of NOX1 or NOX2 had no
impact on infarct size or functional outcome after tMCAO.
Although others have described protective effects of NOX2
deficiency after experimental stroke [42–44], we could not
reproduce those findings. The exact reasons for this discrepancy
are unclear at present. Differences in the experimental protocols
and middle cerebral artery occlusion times, which varied between
30 min and 120 min in previous investigations, might play a role
here [42–44]. In contrast to these previous studies, however, we
used especially high numbers (n=19) of Nox2y/2 mice to verify our
findings. Moreover, type-II (beta) error of the differences between
infarct volumes in Nox2y/2 mice and wild-type controls was only
7% in our study (93% power, respectively) (Tables S3–S5), which
is a very powerful result compared to the positive reports on Nox2
deficiency in cerebral ischemia [42–44] as well as to many other
experimental stroke studies in general [4,45]. Moreover, the fact
that VAS2870, which specifically inhibits NADPH oxidases, could
not further decrease infarct size and ROS formation in Nox42/2
mice ex vivo and in vivo (Figure 4) clearly argues against a major
role of NOX1 or NOX2 in the pathophysiology of acute ischemic
stroke. Finally, protein expression levels of NOX1 and NOX2
were almost unchanged in the brains of Nox42/2 mice (Figure
S3C), underlining that the profound neuroprotection we observed
is mediated by deficiency or blockade of NOX4 itself and not by
secondary effects.
Nevertheless, we cannot completely rule out contributions of
other sources of ROS. Referring to this, Block et al. recently
reported that a functional NOX4 is present and regulated in
mitochondria, indicating the existence of a hitherto undescribed
source of mitochondrial ROS [46].
An unprecedented need exists for more effective therapies for
acute stroke, the second leading cause of death worldwide [1]. We
have demonstrated that pharmacological inhibition of NADPH
oxidases using the specific NADPH oxidase inhibitor VAS2870
[15,32–34] protects mice from brain ischemia within a clinically
meaningful 2-h time window. In contrast, the commonly used
organic compound apocynin may not be a NOX inhibitor in
vascular cells but rather acts as a nonspecific antioxidant [36]. It
also inhibits Rho kinase inhibitor [37], an activity that increases its
nonspecific actions. If apocynin inhibits NADPH oxidases at all, it
supposedly blocks the migration of the cellular NADPH oxidase
complex subunit p47phox to the membrane, thus interfering with
assembly of the functional NOX complex [47]. Therefore, it is
unlikely to inhibit the NOX4-containing NADPH oxidase, which
acts independently of any cytosolic subunits [12]. Indeed, in our
experiments, application of apocynin had no effect on the
Figure 3. Nox4 deficiency confers neuroprotection by reducing oxidative stress, neuronal apoptosis, and disruption of the blood–
brain barrier. (A and B) Left panels show representative brain sections from sham-operated wild-type (WT) mice and wild-type and Nox42/2 mice
24 h after tMCAO. Sections were stained for ROS and oxidative chemistry using dihydroethidium (DHE) (A), or stained for reactive nitrogen species by
using nitrotyrosine (B). Right panels show the number of cells per square millimeter that are positive for ROS or oxidative stress (A) or reactive
nitrogen species (B) in the ischemic hemispheres of sham-operated wild-type mice and wild-type and Nox42/2mice 12 h and 24 h after tMCAO (n=4
per group). (C) Left panels show representative brain sections from sham-operated wild-type mice and wild-type and Nox42/2 mice 24 h after
tMCAO, immunolabeled for the neuronal marker NeuN and subjected to TUNEL to show apoptosis. Right panel shows the number of TUNEL-positive
neurons per square millimeter in the ischemic hemispheres of sham-operated wild-type mice and wild-type and Nox42/2 mice 24 h after tMCAO
(n=4 per group). (D) Left panels show corresponding coronal brain sections of wild-type and Nox42/2 mice on day 1 after tMCAO and injection of
Evans blue. Extravasation of Evans blue was reduced in areas where infarcts were regularly present in Nox42/2mice (basal ganglia, broken white line).
The right panel shows the extent of extravasation (i.e., edema volume) as determined by planimetry in the wild-type and Nox42/2 mice 24 h after
tMCAO (n= 6 per group). For (A–C), ###, p,0.0001, and ##, p,0.001, compared with sham-treated mice; ***, p,0.0001, and **, p,0.001,
compared with wild-type mice by two-way ANOVA, Bonferroni post-hoc test. For (D), **, p,0.001, Two-tailed Student9s t-test, compared with wild-
type mice. All scale bars represent 100 mm.
doi:10.1371/journal.pbio.1000479.g003
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formation of ROS or of functional outcome after experimental
stroke in vivo.
In summary, we have demonstrated that NOX4-derived oxida-
tive stress is a crucial player in the pathophysiology of acute ischemic
stroke, while Nox4 deletion does not affect basal vascular or renal
function. Nox4 gene reconstitution experiments in Nox42/2 mice
and studies of the effects of different, structurally unrelated NOX
inhibitors—should they become available—would be desirable to
further substantiate the causality between NOX4 deficiency and
protection from cerebral ischemia. Pharmacological inhibition of
NADPH oxidases using specific compounds may also pave new
avenues for the treatment of ischemic brain injury in humans.
Because NADPH oxidase–mediated production of ROS may
represent a general mechanism of neurotoxicity, our findings may
extend to other ischemic disorders and neurodegenerative or
inflammatory diseases. Further studies in relevant disease models
are warranted.
Materials and Methods
Refer to the Text S1 for more detailed methodology. The
generation of the Nox4-null mice is described in Figure S3.
Human Specimens
Specimens from patients who had experienced a stroke were
collected during routine autopsy at the Department of Neuropa-
thology, University of Wu¨rzburg, Germany.
Stroke Study Design
Detailed study characteristics are provided in Table S2. We
strictly followed the recent international expert recommendations
for conducting research in mechanism-driven basic stroke studies
[4,6,7,16,17,40].
Stroke Models
If not otherwise mentioned, we performed 60 min of tMCAO in
6- to 8-wk-old male mice weighing 20–25 g, as described
previously [48,49]. To exclude age- and gender-specific effects,
18- to 20-wk-old male and 6- to 8-wk-old female mice were used in
some subgroups. For pMCAO the occluding filament was left in
situ until sacrificing the animals [41].
At 2 h and12 h after the induction of tMCAO, subgroups of
wild-type mice or Nox42/2 mice were randomly selected to receive
either 2 mg of the NOX-specific inhibitor VAS2870 (Vasopharm
GmbH [32,33]) or carrier solution (10% dimethyl sulfoxide,
Sigma) intrathecally, as described previously [50]. In another
group, wild-type mice were injected intravenously with 100 mg of
apocynin 1 h after the occlusion of the middle cerebral artery. In
order to restore ROS levels in Nox42/2 mice, animals received
repetitive intrathecal injections of H2O2 (15 mg/kg) immediately
after the occlusion of the middle cerebral artery and then every
hour until 6 h after stroke induction.
Cortical photothrombosis was induced in 6- to 8-wk-old wild-
type or Nox42/2 mice as described previously [51,52].
Stroke Analysis
Stroke analysis was performed as described previously [53,54]. To
determine infarct size, mice were killed 24 h after tMCAO, pMCAO,
or cortical photothrombosis. Brains were cut in 2-mm-thick coronal
sections using a mouse brain slice matrix (Harvard Apparatus). The
slices were stained with 2% TTC (Sigma-Aldrich) to visualize the
infarcts. Planimetric measurements (ImageJ software, United States
National Institutes of Health), calculating lesion volumes, were
corrected for brain edema as described previously [55].
Determination of brain edema using Evans blue dye was
performed as described previously [19].
Magnetic resonance imaging was performed repeatedly at 24 h
and 6 d after stroke on a 1.5-T magnetic resonance unit (Vision
Siemens) as described previously [56]. We used a custom-made
dual channel surface coil designed for examining mice
(A063HACG; Rapid Biomedical). The imaging protocol com-
prised a coronal T2-weighted sequence (slice thickness 2 mm) and
a blood-sensitive coronal three-dimensional T2-weighted gradient
echo CISS (slice thickness 1 mm) sequence. Magnetic resonance
images were assessed with respect to infarct morphology and the
occurrence of intracerebral bleeding.
Vital Brain Slices
Vital brain slices from infarcted mouse brains (between –2 mm
and –4 mm from bregma) were prepared as described previously
[57].
Quantitative PCR Analysis
After RNA isolation, we quantified NOX4 mRNA expression
using real-time PCR and the TaqMan system (TaqMan Gene
Expression Arrays for murine NOX4, assay ID Mm00479246_m1,
Applied Biosystems), using 18s rRNA (TaqMan Predeveloped Assay
Reagents, part number 4319413E, Applied Biosystems) to normal-
ize the amount of sample RNA.
Histology and Immunohistochemistry
Histology was performed by using formalin-fixed mouse brains
on day 1 after tMCAO. Samples were embedded in paraffin and
Figure 4. The NADPH oxidase inhibitor VAS2870 protects the brain from damage during acute ischemic stroke. (A) Left panel shows
representative images of vital brain slices from sham-operated wild-type (WT) mice and wild-type mice and Nox42/2 mice 12 h after tMCAO. Slices
were incubated ex vivo with VAS2870 (10 mM) or carrier solution (1% DMSO; control) for 30 min and stained with dihydroethidium (DHE) to detect
ROS. Right panel shows number of ROS-positive cells per square millimeter in brain slices from mice in the different treatment groups (n=5 per
group). (B) Upper panel shows representative TTC staining of three corresponding coronal brain sections of wild-type mice treated with (left to right)
carrier solution (10% DMSO; control), 100 mg of apocynin intravenously 1 h after tMCAO, or 2 mg of VAS2870 intrathecally 2 h and 12 h after tMCAO,
untreated Nox42/2 mice, Nox42/2 mice treated with 2 mg of VAS2870 intrathecally 2 h and 12 h after tMCAO, and Nox42/2 mice treated with H2O2
intrathecally (15 mg/kg) immediately after the occlusion of the middle cerebral artery and then every hour until 6 h after stroke induction. Ischemic
infarcts (white) appear smaller (arrows) in VAS2870-treated wild-type mice and Nox42/2 mice than in control mice, but those in apocynin-treated
mice are similar to those in control mice. VAS2870 could not further decrease infarct volumes in Nox42/2 mice. Exogenous H2O2 reversed the stroke-
protective phenotype in Nox42/2 mice. These results were confirmed by infarct volumetry (lower panel) (n= 7–10 per group). (C) Neurological
Bederson score (upper panel) and motor score (lower panel) on day 1 after tMCAO in the different animal groups indicated in (B) (n= 7–10 per group).
(D) Left panel shows representative brain sections from the different animal groups indicated in (B) stained for ROS by using dihydroethidium. Right
panel shows corresponding number of ROS-positive cells per square millimeter in the ischemic hemispheres (n= 3–5 per group). For (A), ###,
p,0.0001, compared with sham-operated mice, ***, p,0.0001 compared with control mice, ns, not significant, one-way ANOVA, Bonferroni post-hoc
test. For (B–D), ***, p,0.0001, **, p,0.001, *, p,0.05, ns, not significant, one-way ANOVA, Bonferroni post-hoc test, compared with controls. All scale
bars represent 100 mm.
doi:10.1371/journal.pbio.1000479.g004
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cut into 4-mm-thick sections (0.5 mm anterior from bregma). After
deparaffinization and rehydration, tissues were stained with
hematoxylin and eosin or Nissl staining solution (Sigma-Aldrich).
Immunohistochemical detection of NOX4 was performed on
formalin-fixed human brain slices or cryopreserved mouse brain
slices. A NOX4-specific primary antibody [58] was applied at a
dilution of 1:200 overnight at 4uC. To identify the cellular origin
we performed double staining of NOX4 with the neuronal marker
NeuN (1:1,000) and the endothelial marker von Willebrand Factor
(1:25).
Oxidative Chemistry Biomarkers
The presence of ROS and other oxidants such as ONOO2 was
visualized on frozen mouse brain sections 12 h and 24 h after
tMCAO or 24 h after pMCAO using dihydroethidium (Sigma;
2 mM stock) staining, as described previously [59], in coronal brain
sections taken from identical regions (–0.5 mm from bregma) of
sham-operated controls, wild-type and Nox42/2 mice that had
undergone stroke, and wild-type mice and Nox42/2 mice treated
with VAS2870 or H2O2.
Immunohistochemical staining for nitrotyrosine to visualize
additional reactive nitrogen species was conducted on cryopre-
served brain sections taken from identical regions of the mouse
brain (–0.5 mm from bregma) 12 h and 24 h after tMCAO, using
a polyclonal nitrotyrosine antibody.
Apoptotic neurons in the ischemic hemisphere 24 h after
tMCAO were visualized by TUNEL on paraffin-wax-embedded
slices, using the TUNEL in situ cell death detection kit, TMR red
(Roche). NeuN/TUNEL double staining was performed on
cryopreserved brain slices.
Quantification of Protein Expression
We quantified amounts of NOX1, NOX2, and NOX4 protein
in the cortex and basal ganglia by Western blot analysis.
Statistical Analysis
Data are expressed as mean 6 standard deviation and were
analyzed statistically using the PrismGraph 4.0 software package
(GraphPad Software). In the case of multiple group comparisons,
data were tested for Gaussian distribution with the D’Agostino and
Pearson omnibus normality test and then analyzed by Bonferroni-
corrected one-way ANOVA or two-way ANOVA. Otherwise, the
two-tailed Student’s t-test was applied. For comparison of survival
curves the log-rank test was used. P-values less than 0.05 were
considered significant. Detailed power and type-II (beta) error
calculations on infarct volumes are provided in Tables S3–S5.
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) acces-
sion numbers for the genes discussed in this paper are NOX1,
NM_172203; NOX2, NM_007807; and NOX4, NM_015760.
Supporting Information
Figure S1 Systemic and pulmonary blood pressure as
well as kidney function in Nox42/2 mice are unchanged.
(A and B) Radiotelemetry recordings of basal mean arterial
pressure (MAP) and heart rate (HR) of wild-type (WT) (open
circles, n=10) and Nox42/2 (filled squares, n=14) mice. Data are
represented as 1-h (A) and 24-h (B) averages of mean arterial
pressure (left panels) and heart rate (right panels). Dark and light
periods are denoted by black and white bars, respectively. (C)
Right ventricular systolic pressure (RVSP) as assessed in vivo in
anaesthetized Nox42/2 and wild-type mice. (D) Mean pulmonary
arterial pressure (PAP) in isolated perfused lungs during normoxic
(21% O2) ventilation. (E) Strength of hypoxic pulmonary
vasoconstriction (HPV) as indicated by the maximum increase in
PAP (DPAP) upon acute hypoxic ventilation (10 min, 1% O2) in
isolated perfused lungs. No significant differences were observed
between wild-type and Nox42/2 mice. Data are derived from six
mice in each case. (F) Renal hypertrophy as assessed by kidney
weight per body surface area (BSA) (g/m2). There was no
significant difference in terms of renal mass between wild-type and
Nox42/2 mice at 17 wk of age. (G) Albuminuria at 17 wk of age
(mg/24 h). There was no significant difference in 24-h urinary
albumin excretion between wild-type and Nox42/2 mice at 17 wk
of age.
Found at: doi:10.1371/journal.pbio.1000479.s001 (1.23 MB TIF)
Figure S2 Cerebral blood flow, cerebral vasculature,
and brain structure are normal in Nox42/2 mice. (A)
Regional cerebral blood flow (rCBF) in the right territory of the
middle cerebral artery as measured by laser Doppler flowmetry in
wild-type (WT) mice and in Nox1y/2, Nox2y/2, and Nox42/2 mice
(n=4 per group) at baseline levels, after insertion of the thread
(ischemia) and again 10 min after removal of the thread
(reperfusion). No significant differences were observed between
the groups at any time point. p.0.05, two-way ANOVA,
Bonferroni post-hoc test, compared with baseline rCBF. (B)
Assessment of the cerebral vasculature in wild-type and Nox42/2
mice. A complete circle of Willis (white arrows) was identified in all
animals studied, and the distribution of the trunk and branch of
the middle cerebral artery appeared to be anatomically identical
among the genotypes. (C) Normal brain structure in Nox42/2
mice. Representative Nissl-stained 5-mm coronal paraffin-wax-
embedded brain sections of 3-mo-old wild-type and Nox42/2 mice
(n=3 each), showing a macroscopic view (uppermost panel),
formation of the hippocampus formation (center panel), and
somatomotor areas of the neocortex (lowermost panel).
Found at: doi:10.1371/journal.pbio.1000479.s002 (1.64 MB TIF)
Figure S3 Generation of Nox4 knockout mice and
counter-regulation of NOX1 and NOX2. (A) Construct
development for Nox4 knockout mice. Exons 14 and 15 are flanked
by loxP sites and followed by a floxed neomycin resistance gene
(neo) and a negative-selection cassette coding for diphtheria toxin A
(dta) as described in the Text S1. Embryonic stem cell clones were
generated by homologous recombination with the targeting vector.
Transient expression of Cre recombinase results in three different
recombination events. Type 1 results in deletion of the neo cassette
and thus floxed exons 14 and 15. These cells can be used to
generate conditional Nox4 knockout. Type 2 results in deletion of
the floxed exons, and type 3 results in the deletion of exons 14 and
15 and the neo cassette. These cells were used to generate the Nox4
knockout mice. (B) Western blot demonstrating the absence of the
64-kDa NOX4 band in the aorta, lung, and kidney of Nox42/2
mice. (C) Expression of NOX1 and NOX2 is not upregulated in
Nox42/2 mice. The uppermost left panel shows results of
densitometric analysis of the NOX1 134-kDa band in brain
samples of the cortex and basal ganglia from Nox42/2 (pale bar)
and wild-type mice (black bar). Data are presented as the relative
amount of the NOX1 band normalized to GAPDH and represent
the mean 6 standard error of three samples. The right panel
shows a Western blot comparison of brain and aorta samples from
wild-type mice demonstrating the presence of the 134-kDa band in
both samples. The center and lowest panels show results of
densitometric analysis of the 91- and 53-kDa NOX2 bands seen in
brain samples from the cortex and basal ganglia of Nox42/2 (pale
bar) and wild-type mice (black bar). Data are presented as the
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relative amount of either the 91-kDa band or 53 k-Da band
normalized to GAPDH and represent the mean 6 standard error
of three samples. The bottom right panel shows a Western blot
comparison of NOX2 expression in the brain and aorta of wild-
type mice, demonstrating the presence of the 91-kDa and 53-kDa
bands in both tissues.
Found at: doi:10.1371/journal.pbio.1000479.s003 (24.75 MB
TIF)
Figure S4 Long-term outcomes are improved in Nox42/2
mice after tMCAO. Long-term outcome of motor function (grip
test) in 6- to 8-wk-old male Nox42/2mice (n=10) and wild-type (WT)
controls (n=15) after tMCAO. Nox42/2 mice performed better over
the whole observation period. **, p,0.001 and *, p,0.05, one-way
ANOVA, Bonferroni post-hoc test compared with wild-type mice.
Found at: doi:10.1371/journal.pbio.1000479.s004 (0.27 MB
TIF)
Figure S5 Motor function after pMCAO. Motor function
was assessed by the grip test in 6- to 8-wk-old male Nox42/2 mice
(n=7) and wild-type (WT) controls (n=11) 24 h after pMCAO.
Two-tailed Student’s t-test compared with wild-type mice. ns, not
significant.
Found at: doi:10.1371/journal.pbio.1000479.s005 (0.18 MB TIF)
Figure S6 Oxidative stress is reduced in brains from
Nox42/2 mice after pMACO. Left panels show representative
brain sections from wild-type (WT) and Nox42/2 mice 24 h after
sham operation of pMCAO. Sections were stained for ROS and
oxidative chemistry using dihydroethidium. Right panel shows the
number of cells per square millimeter that are positive for ROS or
oxidative stress in the ischemic hemisphere of wild-type and Nox42/2
mice 24 h after sham operation or pMCAO (n=3–5 per group).
##, p,0.001 compared with sham-treated mice; **, p,0.001
compared with wild-type mice by one-way ANOVA, Bonferroni
post-hoc test.
Found at: doi:10.1371/journal.pbio.1000479.s006 (1.76 MB
TIF)
Table S1 Results of blood gas analysis and posterior
communicating artery (PComA) score in wild-type and
Nox42/2 mice.
Found at: doi:10.1371/journal.pbio.1000479.s007 (0.04 MB PDF)
Table S2 Stroke study population.
Found at: doi:10.1371/journal.pbio.1000479.s008 (0.09 MB PDF)
Table S3 Power and type-II (beta) error calculations on
infarct volumes depicted in Figure 2A.
Found at: doi:10.1371/journal.pbio.1000479.s009 (0.06 MB PDF)
Table S4 Power and type-II (beta) error calculations on
infarct volumes depicted in Figure 2E.
Found at: doi:10.1371/journal.pbio.1000479.s010 (0.05 MB PDF)
Table S5 Power and type-II (beta) error calculations on
infarct volumes depicted in Figure 4B.
Found at: doi:10.1371/journal.pbio.1000479.s011 (0.06 MB PDF)
Text S1 Supplementary results, supplementary meth-
ods, and supplementary references.
Found at: doi:10.1371/journal.pbio.1000479.s012 (0.32 MB
DOC)
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